Member Spotlight

BIO:

Lyndsey Meyer is a Senior Scientist at Pfizer supporting the Internal Medicine Research Unit in the areas of metabolic disease and heart failure. Lyndsey graduated from Binghamton University with a BS degree in Biochemistry before obtaining her PhD in Pharmaceutical Sciences from the University at Buffalo under the guidance of Dr. Dhaval Shah. At Buffalo, her thesis focused on understanding the mechanism of weight loss with oxidative phosphorylation uncouplers for the treatment obesity. Her research leveraged techniques spanning from in vitro cell culture of adipocytes to in vivo experiments to mathematical modeling to evaluate the pharmacokinetic-pharmacodynamic (PK-PD) relationship of uncouplers and weight loss. During the summer of 2018, Lyndsey joined the Quantitative Systems Pharmacology (QSP) group at Pfizer as a summer student worker investigating fibrosis progression in NAFLD and NASH. In March of 2019, Lyndsey joined the QSP group full-time as a Postdoctoral Fellow where her project investigated the role of mitochondrial metabolism in heart failure through the development and analysis of mathematical models of metabolism. In her current role, she explores mechanisms in the exploratory and early clinical space to support Pfizer in bringing safe and efficacious medicines to patients.

Why are you an ISoP member?
I joined the ISoP community to meet and connect with people that have similar interests and a variety of technical skills. The ISoP community brings together scientists with diverse educational backgrounds and provides so many opportunities to learn something new. I’ve had the privilege to participate in and present at a few ACoP conferences and found that there is always a strong sense of community. I always look forward to ISoP meetings for the exciting talks and new connections.